Abstract
Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clinical practice has resulted in a wide variance of antithrombotic treatment approaches. Procedural interruption of anticoagulants, switching of anticoagulation scheme (i.e. from novel oral anticoagulants to vitamin K antagonists), bridging with heparin, timing of re-initiation of therapy and/or utilization of novel oral anticoagulants have all been points of dispute. In the present review we present the available data regarding optimal peri-procedural anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation.
Keywords: Radiofrequency, cryoablation, VKA, NOAC, warfarin, dabigatran, rivaroxaban, apixaban.
Current Pharmaceutical Design
Title:Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review
Volume: 23 Issue: 9
Author(s): Dimitrios A. Vrachatis*, Georgios Giannopoulos, Charalambos Kossyvakis, Vasiliki Panagopoulou, Manolis Vavuranakis, Theodore G. Papaioannou, Stamatina Pagoni, Vlasios N. Pyrgakis, Michael W. Cleman and Spyridon G. Deftereos
Affiliation:
- Department of Cardiology, “G. Gennimatas” General Hospital of Athens, 154 Mesogion ave., 115 27, Athens,Greece
Keywords: Radiofrequency, cryoablation, VKA, NOAC, warfarin, dabigatran, rivaroxaban, apixaban.
Abstract: Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clinical practice has resulted in a wide variance of antithrombotic treatment approaches. Procedural interruption of anticoagulants, switching of anticoagulation scheme (i.e. from novel oral anticoagulants to vitamin K antagonists), bridging with heparin, timing of re-initiation of therapy and/or utilization of novel oral anticoagulants have all been points of dispute. In the present review we present the available data regarding optimal peri-procedural anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation.
Export Options
About this article
Cite this article as:
Vrachatis A. Dimitrios*, Giannopoulos Georgios, Kossyvakis Charalambos, Panagopoulou Vasiliki, Vavuranakis Manolis, Papaioannou G. Theodore, Pagoni Stamatina, Pyrgakis N. Vlasios, Cleman W. Michael and Deftereos G. Spyridon, Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review, Current Pharmaceutical Design 2017; 23 (9) . https://dx.doi.org/10.2174/1381612822666161205115101
DOI https://dx.doi.org/10.2174/1381612822666161205115101 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plasma Acetylcholinesterase Activity Correlates with Intracerebral β-Amyloid Load
Current Alzheimer Research Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans
Current Drug Metabolism Structure and Bioactivities of Porphyrans and Oligoporphyrans
Current Pharmaceutical Design Early Brain Injury or Vasospasm? An Overview of Common Mechanisms
Current Drug Targets Recent Aspects of Osmotic Pump Systems: Functionalization, Clinical use and Advanced Imaging Technology
Current Drug Metabolism Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Perioperative Management of Hyperlipidemia Medications
Current Clinical Pharmacology Modulation of Platelet Function and Signaling by Flavonoids
Mini-Reviews in Medicinal Chemistry Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery Potential Role of Cardiovascular Imaging in Improving Cardiovascular Outcome in Coronary Artery Disease
Current Pharmaceutical Design Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease
Current Medicinal Chemistry Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Estrogens and Glucocorticoid Hormones in Adipose Tissue Metabolism
Current Medicinal Chemistry Mitochondria: A Target for Neuroprotective Interventions in Cerebral Ischemia-Reperfusion
Current Pharmaceutical Design Evaluation of a Standardized Protocol Using Lepirudin or Argatroban for Heparin-Induced Thrombocytopenia
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Coagulation and Fibrinolysis in the Pathogenesis of Acute Lung Injury
Current Respiratory Medicine Reviews Neuropathic Pain: Models and Mechanisms
Current Pharmaceutical Design Protease Inhibitors with Antileishmanial Activity
Current Enzyme Inhibition